Shareholder Information

As at 30 April 2019

Abcam plc is both the UK operating company and the holding company for the group. There are a number of trading subsidiaries, which are 100 per cent owned by Abcam plc; a full list can be found in the annual report which can be downloaded here.

The Company’s issued share capital at the above date was 205,597,614 ordinary shares of 0.2 pence each. The percentage of shares not held in public hands (as defined by AIM rule 26) was 23.05%. The Company has nil treasury shares, and there are no restrictions on transfers of ordinary shares.

Shareholders with more than 3% holding (as at 30 April 2019) were:

 Shareholder  Total interest  % issued shared  capital
 T Rowe Price Associates, Inc 26,150,266 12.72%
 Jonathan Milner (Director) 19,932,815 9.70%
 Standard Life Aberdeen 11,339,493 5.52%
 Baillie Gifford & Co 10,149,863 4.94%
 Wasatch Advisors 7,965,132 3.87%
 OppenheimerFunds Inc 7,278,960 3.54%
 Harding Loevner 6,361,100 3.09%

About Abcam

Abcam is a producer and marketer of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level which is essential in a wide range of fields including drug discovery, diagnostics, and basic research.

Read more +

Abcam Products

As an innovator in reagents and tools, Abcam offers highly validated binders and assays to address important targets in critical biological pathways.

Read more +

Investor Information

Abcam is listed on the AIM market of the London Stock Exchange under the ticker ABC, and our investors' centre includes a range of information on our company, including our news, financial reports and investor contacts

Read more +

Abcam News

We provide updates on our commercial and financial progress through regular press releases which can be accessed through the Company's media centre.

Read more +